2024
Hypertension and risk of endometrial cancer: a pooled analysis in the Epidemiology of Endometrial Cancer Consortium (E2C2)
Habeshian T, Peeri N, De Vivo I, Schouten L, Shu X, Cote M, Bertrand K, Chen Y, Clarke M, Clendenen T, Cook L, Costas L, Dal Maso L, Freudenheim J, Friedenreich C, Gallagher G, Gierach G, Goodman M, Jordan S, La Vecchia C, Lacey J, Levi F, Liao L, Lipworth L, Lu L, Matias-Guiu X, Moysich K, Mutter G, Na R, Naduparambil J, Negri E, O'Connell K, O'Mara T, Hernández I, Palmer J, Parazzini F, Patel A, Penney K, Prizment A, Ricceri F, Risch H, Sacerdote C, Sandin S, Stolzenberg-Solomon R, van den Brandt P, Webb P, Wentzensen N, Wijayabahu A, Wilkens L, Xu W, Yu H, Zeleniuch-Jacquotte A, Zheng W, Du M, Setiawan V. Hypertension and risk of endometrial cancer: a pooled analysis in the Epidemiology of Endometrial Cancer Consortium (E2C2). Cancer Epidemiology Biomarkers & Prevention 2024, 33: 788-795. PMID: 38530242, PMCID: PMC11145161, DOI: 10.1158/1055-9965.epi-23-1444.Peer-Reviewed Original ResearchConceptsEpidemiology of Endometrial Cancer ConsortiumRisk of endometrial cancerComponents of metabolic syndromeCancer ConsortiumRisk factorsAssociated with endometrial cancer riskIncidence rates of endometrial cancerMultivariable unconditional logistic regression modelStronger magnitude of associationEtiology of endometrial cancerStudy designUnconditional logistic regression modelsIncreased risk of endometrial cancerEndometrial cancer riskRates of endometrial cancerUsers of postmenopausal hormone therapyConfidence intervalsRising prevalence of obesityPrevalence of obesityEndometrial cancerMagnitude of associationEndometrial cancer casesMetabolic syndromeBody mass indexLogistic regression models
1997
Detection of Prostate Cancer Relapse With Prostate Specific Antigen Monitoring at Levels of 0.001 to 0.1 micro g./l
Yu H, Diamandis E, Wong P, Nam R, Trachtenberg J. Detection of Prostate Cancer Relapse With Prostate Specific Antigen Monitoring at Levels of 0.001 to 0.1 micro g./l. Journal Of Urology 1997, 157: 913-918. PMID: 9072598, DOI: 10.1016/s0022-5347(01)65082-1.Peer-Reviewed Original ResearchConceptsProstate-specific antigenPositive surgical marginsPreoperative prostate-specific antigenSerum prostate-specific antigenSerial serum samplesBiochemical relapseSurgical marginsClinicopathological featuresRadical prostatectomyTumor volumeLogistic regression modelsPSA changeGreater preoperative prostate specific antigenPostoperative serum prostate-specific antigenHigher preoperative prostate-specific antigenPostoperative prostate-specific antigenUnconditional logistic regression modelsSerum samplesProstate-specific antigen monitoringSerum PSA changesSubset of patientsUnivariate logistic regression modelYear of surgeryLength of followupConventional prostate specific antigenDetection of Prostate Cancer Relapse With Prostate Specific Antigen Monitoring at Levels of 0.001 to 0.1 micro g./l
Yu H, Diamandis E, Wong P, Nam R, Trachtenberg J. Detection of Prostate Cancer Relapse With Prostate Specific Antigen Monitoring at Levels of 0.001 to 0.1 micro g./l. Journal Of Urology 1997, 157: 913-918.. DOI: 10.1097/00005392-199703000-00047.Peer-Reviewed Original ResearchProstate-specific antigenPositive surgical marginsPreoperative prostate-specific antigenSerum prostate-specific antigenSerial serum samplesBiochemical relapseMicro g.Clinicopathological featuresSurgical marginsRadical prostatectomyTumor volumeLogistic regression modelsPSA changeGreater preoperative prostate specific antigenPostoperative serum prostate-specific antigenHigher preoperative prostate-specific antigenPostoperative prostate-specific antigenUnconditional logistic regression modelsSerum samplesProstate-specific antigen monitoringSerum PSA changesUnivariate logistic regression modelYear of surgerySubset of patientsLength of followup
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply